Selective Actions of Mitochondrial Fission/Fusion Genes on Metabolism-Secrecion Coupling in Insulin-releasing Cells

Kyu-Sang Park, Andreas Wiederkehr, Clare Kirkpatrick, Yves Mattenberger, Jean-Claude Martinou, Piero Marchetti, Nicolas Demaurex, and Clae Wollheim

From the Departments of Cell Physiology and Metabolism and Cell Biology, University of Geneva, CH-1211, Geneva 4, Switzerland, and Department of Endocrinology and Metabolism, University of Pisa, 56126 Pisa, Italy

Mitochondria form filamentous networks that undergo continuous fission/fusion. In the pancreatic β-cells, mitochondria are essential for the transduction of signals linking nutrient metabolism to insulin granule exocytosis. Here we have studied mitochondrial networks in the insulinoma cell line INS-1E, primary rat and human β-cells. We have further investigated the impact of mitochondrial fission/fusion on metabolism-secretion coupling in INS-1E cells. Overexpression of hFis1 caused dramatic mitochondrial fragmentation, whereas Mfn1 evoked hyperfusion and the aggregation of mitochondria. Cells overexpressing hFis1 or Mfn1 showed reduced mitochondrial volume, lowered cellular ATP levels, and as a consequence, impaired glucose-stimulated insulin secretion. Decreased mitochondrial ATP generation was partially compensated for by enhanced glycolysis as indicated by increased lactate production in these cells. Dominant-negative Mfn1 elicited mitochondrial shortening and fragmentation of INS-1E cell mitochondria, similar to hFis1. However, the mitochondrial volume, cytosolic ATP levels, and glucose-stimulated insulin secretion were little affected. We conclude that mitochondrial fragmentation per se does not impair metabolism-secretion coupling. Through their impact on mitochondrial bioenergetics and distribution, hFis1 and Mfn1 activities influence mitochondrial signal generation thereby insulin exocytosis.

Mitochondria play a central role in energy metabolism, other biosynthetic processes, Ca\(^{2+}\) signaling, and the integration of diverse apoptotic stimuli. Mitochondria establish networks of filamentous structures that continuously move, divide, and fuse. This continuous remodeling is under the control of several fission and fusion proteins. The major components of the fission machinery are Fis1 and Drp1 (dynamin-related protein 1) (4). Fis1 is a small (17-kDa) protein, anchored in the outer mitochondrial membrane (5). Drp1 has a dynamin-like central domain and a C-terminal GTPase domain, which couples GTP hydrolysis to mitochondrial membrane constriction during fission (6). In the mitochondrial fission process, Fis1 has been suggested to be a limiting factor. The number of expressed Fis1 molecules on the mitochondrial outer surface determines the frequency of mitochondrial fission (5).

Mitochondrial fusion is regulated by mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2) as well as Opa1 (2). Mfn1 and Mfn2 are GTPases localized to the outer mitochondrial membrane that form homo- or hetero-oligomeric complexes during the fusion process. Mfn1 has higher GTPase activity and causes more efficient fusion than Mfn2 (7). Suppression of mitofusin function promotes fission, yielding highly fragmented mitochondria (8). A point mutation in the GTPase domain of Mfn1 (Mfn1T109A) allows the protein to act as a dominant-negative, inducing excessive fission when overexpressed (9).

The biological impact of the mitochondrial fission/fusion process is not restricted to structural changes. Fission and fusion allow mitochondria to exchange lipid membranes and intramitochondrial content including mtDNA (2). Thus, damage in the organelle can be restored by fusion with healthy mitochondria (10). Furthermore, dysfunctional parts of the reticulum can be separated by fission and selectively targeted to autophagy, which may protect cells from apoptosis by preventing the release of proapoptotic proteins (11, 12). Mitochondrial dynamics are also important during apoptosis as the organelle undergoes massive fragmentation during this process. For instance, overexpression of fission protein leads to apoptosis. Mitochondrial fission/fusion proteins also directly or indirectly influence mitochondrial energy metabolism. Knock-out or down-regulation of fission or fusion proteins reduces mitochondrial respiration and ATP generation (13–15).

Filamentous mitochondrial networks have also been observed in the pancreatic β-cell (16), and a recent electron microscope tomography study further described branched mitochondria in β-cells within the islet (17). In this cell type, mitochondria are of particular importance as they are both the center of energy production as well as the source of coupling factors that link nutrient metabolism to insulin exocytosis. Because of extremely low lactate dehydrogenase levels, more than 90% of glucose-derived carbons are funneled into the β-cell mitochondria (18, 19). mtDNA-depleted β-cell lines showed complete absence of glucose-stimulated insulin secretion, illustrating the importance of the organelle in signal gen-
Mitochondrial Fission and Insulin Release

ereation (20). Moreover, patients having mtDNA mutations develop diabetes. The prevalence of mitochondrial diabetes varies between populations, accounting for up to 1% of diabetes cases (21, 22). In addition, postmortem islets from type 2 diabetes patients display ultrastructural changes in mitochondria and reduced glucose-stimulated insulin secretion resulting from reduced glucose oxidation and attenuated ATP generation (23–25).

In islets from the Zucker diabetic fatty rat, β-cell mitochondria are fragmented into smaller units when compared with those of control animals (16). These studies give a first insight into the possible importance of mitochondrial structure and dynamics for β-cell function, also raising the question whether mitochondrial structural changes contribute to the defects of the β-cell in the diabetic state. Here we have studied mitochondrial morphology in primary human and rat cells as well as INS-1E cells. Furthermore, we have manipulated the mitochondrial filamentous network and analyzed the impact of the resulting mitochondrial morphology changes on cell viability and metabolism-secretion coupling in INS-1E cells. The mitochondrial network was manipulated by overexpression of either hFis1 or dominant-negative Mfn1 (DN-Mfn1; Mfn1T109A). Overexpression of hFis1 deteriorated mitochondrial signal generation and insulin secretion, also causing a limited degree of apoptosis, whereas such changes were not observed in DN-Mfn1-overexpressing cells. We suggest that hFis1 induces a specific metabolic defect in the β-cell. This defect is not simply due to fragmentation of the mitochondria as massive fragmentation caused by DN-Mfn1 did not mimic any of these defects.

EXPERIMENTAL PROCEDURES

Cell Culture and Transfection—Human pancreatic islets were isolated from two different donors obtained through the EURODIA European Union sixth framework programme consortium (25). Rat islets were isolated from male Wistar rats (250 g, Elevage Janvier, Le Genest-St-Isle, France) after collagenase digestion. Islets were dissociated with 0.02% trypsin and seeded on coverslips coated with A431 cell-derived extracellular matrix (26). Human islet cells were cultured in CMRL-1066 (Invitrogen) medium at 5.6 mM glucose supplemented with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 100 µg/ml gentamycin (Sigma). Rat islet cells were cultured in RPMI 1640 (11.1 mM glucose, Invitrogen) supplemented with 10% fetal calf serum and antibiotics. INS-1E cells were cultured in a humidified atmosphere (37 °C) containing 5% CO2 in complete medium composed of 2.8 mM glucose, 10 mM HEPES, 100 units/ml penicillin, 100 µg/ml streptomycin, and 100 µg/ml gentamycin (Sigma). INS-1E cells were seeded in 24-well plates (3 × 105 cells/well) and transfected with AAV vectors. After 48 h, infected cells were preincubated with glucose-free medium for 2 h subsequently with KRB buffer (135 mM NaCl, 3.6 mM KCl, 2 mM NaHCO3, 0.5 mM Na2HPO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 10 mM HEPES, pH 7.4, and 0.1% bovine serum albumin) containing 2.8 mM glucose for 30 min. The cells were then stimulated for 30 min in KRB buffer at different glucose concentrations. Insulin was measured by rat insulin enzyme immunoassay kit (Spi-Bio, Montigny le Bretonneux, France).

Cellular ATP Content and Lactate Production—For the measurement of ATP content and lactate production, INS-1E cells were prepared as described for insulin secretion. Total cellular ATP was measured using a bioluminescence assay kit according to the manufacturer’s instructions (HS II, Roche Diagnostics). Lactate in the cell supernatant was measured using a lactate assay kit (BioVision, Mountain View, CA).

Measurement of Mitochondrial Membrane Potential—INS-1E cells were seeded (5 × 104 cells/well) on black-walled 96-well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) and infected with adenoviruses. Cells were cultured for 48 h and then loaded with 500 nM JC-1 (Invitrogen) in KRB buffer (2.8 mM glucose) for 30 min at 37 °C. After washing twice, JC-1 fluorescence was measured ratiometrically using a Flex

*The abbreviations used are: DN, dominant-negative; WT, wild type; ECFP, mitochondrial targeted enhanced cyan fluorescent protein; mitoECFP, mitochondrial targeted ECFP; RFP, red fluorescent protein; mitoRFP, mitochondrial RFP; FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling.

mycin. Transient transfection of INS-1E cells was performed using the LipofectamineTM 2000 reagent (Invitrogen).

Adenovirus Construction and Infection—Doxycycline-inducible adenoviruses encoding hFis1, WT-Mfn1, and DN-Mfn1 were constructed using the Adeno-X Tet-On expression system (Clontech Laboratories, Inc.). Adenoviruses encoding the transgene were applied together with the adenovirus expressing the reverse tetracycline-transactivator (Clontech laboratories, Inc.) to islet cells and INS-1E cells for 90–120 min 1 day after seeding (27).

Mitochondrial Morphology—Mitochondria of human and rat islet cells were visualized following infection with adenovirus encoding enhanced cyan fluorescence protein (mitoECFP). Human β-cells were identified by immunohistochemical staining of insulin as described previously (28). INS-1E cells were transfected with mitochondria-targeted red fluorescence protein (mitoRFP) plasmid followed by infection with adenoviruses. Mitochondrial morphology was observed 48 h after infection and analyzed using a confocal laser-scanning microscope (LSM510meta, Zeiss, Zurich, Switzerland) after fixation with 4% paraformaldehyde. Mitochondrial volume and skeleton length were calculated as described in supplemental Figs. S3 and S4.

Western Blot—Total protein extracts (50 µg) were resolved by 11% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked in 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.1% Tween 20, 5% milk and then incubated with first antibodies: anti-glyceraldehyde-3-phosphate dehydrogenase (1:8000; Sigma), anti-hFis1 (1:1000) (29), or anti-Mfn1 (1:1000), a generous gift from Dr. D. C. Chan (California Institute of Technology, Pasadena, CA). Anti-chicken and anti-rabbit IgG-horseradish peroxidase conjugates (Sigma) were used as secondary antibodies.

Glucose-stimulated Insulin Secretion—INS-1E cells seeded on 24-well plates (3 × 105 cells/well) were infected with adenoviruses. After 48 h, infected cells were preincubated with glucose-free medium for 2 h subsequently with KRB buffer (135 mM NaCl, 3.6 mM KCl, 2 mM NaHCO3, 0.5 mM Na2HPO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 10 mM HEPES, pH 7.4, and 0.1% bovine serum albumin) containing 2.8 mM glucose for 30 min. The cells were then stimulated for 30 min in KRB buffer at different glucose concentrations. Insulin was measured by rat insulin enzyme immunoassay kit (Spi-Bio, Montigny le Bretonneux, France).
Station (Molecular Devices) with excitation/emission wavelengths of 490/540 nm (green; monomer) and 540/590 nm (red; J-aggregates). Changes in fluorescence ratios from basal levels were normalized to ratio differences between resting and maximal depolarization induced by 10 μM FCCP, and expressed as the percentage of changes \( \frac{(R_{\text{FCCP}} - R_0)}{R_0} \times 100 \) (30).

**Measurement of Cytosolic and Mitochondrial Calcium Concentration**—Cytosolic calcium \( [\text{Ca}^{2+}]_i \) was measured using “yellow cameleon” (YC3.6). Cells grown on glass coverslips were transiently co-transfected with mitochondrial fission genes, mitoRFP and YC3.6, and cultured for 72 h. The cells were placed on an inverted microscope (Axiovert 200 m, Zeiss) equipped with an array laser confocal spinning disk (QLC100; VisiTech, Sunderland, UK). Cells expressing YC3.6 were excited at 440 nm. The fluorescent images were acquired at 490 and 535 nm emission wavelengths using a cooled charge-coupled device camera (CoolSnap HQ; Roper Scientific, Trenton, NJ) and analyzed using Metamorph software (Molecular Devices). \( [\text{Ca}^{2+}]_i \) was calculated from the intensity ratio of two emission wavelengths \( \frac{F_{535}}{F_{490}} \) according to Nagai et al. (31). Mitochondrial calcium \( [\text{Ca}^{2+}]_{\text{mito}} \) was measured using mitochondrial-targeted aequorin as described (28).

**Data Analysis**—Data are presented as means ± S.E. Statistical significance was determined using Student’s t test. \( p < 0.05 \) was considered significant.

**RESULTS**

**Mitochondrial Morphology in Pancreatic β-Cells and INS-1E Cells**—To visualize the mitochondria of primary pancreatic β-cells, we generated a virus encoding mitoECFP. ECFP-labeled mitochondria formed tubular networks throughout the cytosol in the majority of human and rat β-cells (Fig. 1A and supplemental Fig. S1). β-cells were identified by immunofluorescence labeling with an insulin antibody (Fig. 1A). The rat clonal β-cell line INS-1E displays a similar filamentous pattern of mitochondrial distribution as analyzed either with the mitoECFP virus or following transient transfection of mitoRFP (Fig. 2A and data not shown). To manipulate the mitochondrial filamentous network, INS-1E cells were co-transfected with genes of the fission/fusion machinery and mitoRFP. Overexpression of hFis1, DN-Mfn1, or Drp1 caused mitochondrial fragmentation in a large fraction of transfected cells (Fig. 2A, supplemental Fig. S2, A and B). In contrast, overexpression of WT-Mfn1 and WT-Mfn2 caused the aggregation of mitochondria (Fig. 2A and supplemental Fig. S2B).

Among the fission/fusion genes tested, we decided to further focus on the role of hFis1 and DN-Mfn1 in insulin-secreting cells. First, we focused on them because hFis1 and Mfn1 mediate key, possibly rate-limiting, steps in fission and fusion,
respectively. Second, they induced a pronounced effect on mitochondrial morphology in the majority of the expressing cells (supplemental Fig. S2, A and B). Third, we focused on them because hFis1 and DN-Mfn1 utilize different mechanisms to cause a very similar fragmentation phenotype. Overexpression of Mfn1 was further studied as it caused a mitochondrial morphology defect different from the other two transgenes. For this purpose, we generated adenoviruses for doxycycline-inducible expression of the transgenes in whole populations of INS-1E cells and primary β-cells. Doxycycline-dependent induction of hFis1 (17-kDa) and DN-Mfn1 (84-kDa) protein following infection of INS-1E cells is shown in Fig. 1C. Virus-mediated expression of the transgenes caused morphological changes of the mitochondria in INS-1E cells similar to those observed after transient transfection (Fig. 2B). Similarly, hFis1 overexpression led to the fragmentation of mitochondria in human (Fig. 1B) and rat β-cells (supplemental Fig. S1B). To get a quantitative read-out of the fragmentation phenotype in individual cells, we measured the average length of mitochondria. For this purpose, the mitochondria were “skeletonized” using MetaMorph as illustrated in supplemental Fig. S3. This technique allows us to study relative length changes of mitochondria, albeit without taking into consideration mitochondrial distribution over several planes of the z axis. Mean mitochondrial skeleton length of human pancreatic β-cells and rat β-cells was markedly decreased by the overexpression of hFis1 (Fig. 1D and supplemental Fig. S1C). Adenovirus-driven overexpression of hFis1 or DN-Mfn1 elicited similar mitochondrial shortening and fragmentation in INS-1E cells (Fig. 2C). Despite the comparable fragmentation phenotype after induction of either of these two transgenes, we noticed that hFis1 overexpression reduced the mitochondrial area (mitoRFP staining) in the INS-1E cells, possibly reflect-
FIGURE 3. hFis1 overexpression reduces cellular ATP content and increases lactate production. After infection with adenovirus coding for hFis1, DN-Mfn1, or WT-Mfn1, INS-1E cells were incubated for 48 h with or without doxycycline (500 ng/ml). A, ATP contents were measured 10 min after stimulation with 2.8 mM (basal) or 16.5 mM glucose. Cellular ATP was normalized to the DNA content and expressed as the percentage of control for each group (basal level in non-induced cells; n = 7). B, lactate production after a 10-min incubation with either 5.5 mM or 16.5 mM glucose was normalized to the DNA content (pmol of lactate/µg of DNA (n = 6)). Data are presented as means ± S.E. * and ** denote p < 0.05 and p < 0.01, respectively.

Mitochondrial Fission and Insulin Release

A

B

FIGURE 2. Mitochondrial morphology in INS-1E cells overexpressing fission/fusion genes. INS-1E cells were transiently transfected with mitoRFP to visualize the mitochondria. Following adenovirus infection, the fission/fusion proteins were induced by 500 ng/ml doxycycline for 48 h, and morphological changes were studied. A, representative confocal images show mitochondrial distribution and structure in cells after overexpression of hFis1, WT-Mfn1, and DN-Mfn1. B, the number of cells with tubular, shortened (rod shape), or fragmented (small round) mitochondria is expressed as the percentage of total mitoRFP-transfected cells (left and middle graph). Cells with clumped (aggregated) mitochondria were counted following induction of WT-Mfn1 (right graph). Data are presented as means ± S.E. (n = 6, for each experiment, more than 200 cells were counted). Mitochondrial volume normalized to cytosol was calculated from deconvoluted 2-stack confocal images (see supplemental Fig. S4). Mean mitochondrial length (C) and mitochondrial volume (D) were compared between cells expressing different transgenes.
Thus, the hFis1- and Mfn1-dependent mitochondrial defect in JC-1, allowing ratiometric recording. Doxycycline induction of Oligomycin stimulation (36). To estimate the impact of mitochondrial fragmentation (36). To test whether the observed reduction of ATP levels at low and high glucose concentrations affects downstream signals in mitochondrial function, whereas defective fusion secondary to DN-Mfn1 overexpression does not.

hFis1 Reduced Glucose-stimulated Cytosolic and Mitochondrial Calcium Responses—ATP acts as a central signal linking nutrient metabolism to plasma-membrane depolarization, calcium influx, and insulin exocytosis (38). Despite their defect in mitochondrial energy metabolism, hFis1-overexpressing cells still display a glucose-dependent increase in ATP generation. To test whether the observed reduction of ATP levels at low and high glucose concentrations affects downstream signals in metabolism-secretion coupling, we measured cytosolic and mitochondrial calcium. The cytosolic calcium concentration ([Ca^{2+}]_i) was analyzed following transient co-transfection of hFis1 with the yellow cameleon probe YC3.6 and mitoRFP (to analyze the fragmentation state of the mitochondria). In control cells, glucose evoked high frequency calcium transients or slow [Ca^{2+}]_i oscillations (Fig. 5A). Cells with fragmented mitochondria due to overexpression of hFis1 showed significantly lower amplitude of [Ca^{2+}]_i transients when compared with the control cells (Fig. 5B). To quantify this phenotype, we integrated the signal above basal during 10 min after glucose addition (in Fig. 5, AUC indicates area under the curve). The area under the curve in response to glucose was reduced by 52% in hFis1-overexpressing cells when compared with control cells (p < 0.05; Fig. 5C). DN-Mfn1-induced mitochondrial fragmentation did not reduce glucose-stimulated [Ca^{2+}]_i transients (data not shown). We also used KCl (30 mM), a stimulus that directly depolarizes the plasma membrane without requiring cellular metabolism (20). KCl caused a marked increase in [Ca^{2+}]_i, which was not significantly altered by hFis1 transfection (Fig. 5C). These results show that voltage-gated Ca^{2+} influx is unaffected, attributing the attenuated action of glucose to defective mitochondrial function.
Mitochondrial Fission and Insulin Release

Mitochondrial calcium is an important signal in β-cell metabolism-secretion coupling with a potential feedback stimulatory effect on mitochondrial metabolism (28, 38). We therefore tested whether hFis1 overexpression alters the mitochondrial calcium response to glucose or KCl. In non-induced control cells, glucose rapidly increased the average mitochondrial calcium concentration $\langle [Ca^{2+}]_{mito} \rangle$ from $195 \pm 8$ nM to a peak amplitude of $1062 \pm 75$ nM, which thereafter gradually returned to resting levels (Fig. 5, A and C). Doxycycline-induced overexpression of hFis1 resulted in a modest elevation of the resting $[Ca^{2+}]_{mito}$ levels (226 ± 13 nM; $p < 0.05$) and in a lowering of the peak $Ca^{2+}$ response (839 ± 55 nM; $p < 0.05$; Fig. 5E). The glucose-mediated area under the curve increase of $[Ca^{2+}]_{mito}$ was reduced by 33% in hFis1-overexpressing cells ($p < 0.01$; Fig. 5F). Mitochondrial calcium responses to KCl were unchanged after hFis1 overexpression (Fig. 5F).

hFis1, but Not DN-Mfn1, Reduced Glucose-stimulated Insulin Secretion—Based on the reduced ATP levels in hFis1-overexpressing cells and the corresponding reduced cytosolic calcium responses, we tested whether glucose-stimulated insulin secretion is affected by hFis1-dependent mitochondrial fragmentation. Initially, experiments were performed by transiently co-transfecting plasmids encoding mitochondrial fission proteins and human growth hormone. This hormone was used as a marker for insulin in the subpopulation of transiently co-transfected cells since human growth hormone is co-stored with insulin in the secretory granules (39).

hFis1 but not DN-Mfn1 overexpression in INS-1E cells decreased glucose-mediated release of human growth hormone containing granules both at intermediate and at high glucose concentrations (supplemental Fig. S6). Similar experiments were then performed using the doxycycline-inducible adenoviral vectors. The insulin content was reduced by 12% following induction of hFis1 (3.09 ± 0.24 in non-induced versus 2.72 ± 0.26 μg/well in induced cells, $n = 7, p < 0.01$). These results reflect the observed cell death caused by hFis1 and are consistent with the 10% reduction of DNA content as described earlier. Glucose-stimulated insulin release was therefore expressed as the percentage of cellular content to correct for hFis1-mediated cell loss (Fig. 6). In hFis1 infected non-induced control cells, insulin secretion was increased 2.3-fold when the glucose concentration was raised from 2.8 to 16.5 mM. After induction of hFis1, the glucose effect was reduced to 1.6-fold ($p < 0.01$; Fig. 6A). Shifting cells expressing DN-Mfn1 from 2.8 to 16.5 mM glucose resulted in 2.4-fold increase in insulin secretion (Fig. 6B), which did not differ from control. WT-Mfn1 overexpression attenuated the ratio of glucose-stimulated insulin release to 1.5-fold ($p < 0.01$; Fig. 6C). Our results demonstrate that hFis1 causes a specific defect in metabolism-secretion coupling resulting in defective insulin secretion beyond and above its effect on cell viability. In contrast, the similar mitochondrial phenotype induced by DN-Mfn1 did not affect metabolism-secretion coupling.
Mitochondrial Fission and Insulin Release

FIGURE 6. Alteration in glucose-stimulated insulin release by adenoviral-driven overexpression of mitochondrial fission/fusion genes. After infection with adenovirus expressing hFis1 (A; n = 7), DN-Mfn1 (B; n = 7), or WT-Mfn1 (C; n = 6), INS-1E cells were incubated with or without doxycycline (500 ng/ml) for 48 h. Insulin release was measured at 2.8 and 16.5 mM glucose. Insulin release was normalized to the cellular insulin content. Data presented are means ± S.E., and ** denotes p < 0.01.

DISCUSSION

Here we investigated the role of the mitochondrial network in the physiological regulation of glucose-stimulated insulin secretion, a process depending on oxidative phosphorylation. Overexpression or suppression of fission/fusion proteins can shift the mitochondrial structure from an extensive network to fragmented and isolated mitochondria. We demonstrate that human β-cells display elongated and filamnetous mitochondria distributed throughout the cytoplasm. To our knowledge, mitochondrial networks have not been described in human β-cells previously. Rat β-cells also show tubular mitochondrial structure, which is consistent with the observation by Bindokas et al. (16) in islets from lean rats stained with rhodamine 123. The extent of mitochondrial elongation varied between human β-cells. Overexpression of hFis1 invariably caused pronounced fragmentation of the organelle in both primary β-cells and INS-1E cells. The extent of mitochondrial shortening and mitochondrial fragmentation was similarly changed when fusion was inhibited after overexpression of DN-Mfn1 in INS-1E cells, consistent with earlier findings in HeLa cells (9).

hFis1 overexpression caused inhibition of glucose-induced insulin release, explained by attenuated nutrient-dependent hyperpolarization of the ΔΨm and reduced cytosolic and mitochondrial Ca2+ signals. The calcium signaling defects are the result of impaired mitochondrial metabolism as K+-induced cytosolic and mitochondrial Ca2+ increases were unaffected. In contrast, DN-Mfn1 expression preserved mitochondrial hyperpolarization and cellular ATP levels as well as a normal secretory response to glucose.

Oligomycin causes depolarization in dysfunctional mitochondria, which consume cytosolic ATP to maintain the ΔΨm by reversal of the F0F1-ATPase. Thus, evaluating the changes in ΔΨm by oligomycin could uncover latent mitochondrial defects (37, 40). Indeed, hyperpolarization in response to oligomycin was abolished in hFis1-overexpressing cells, consistent with previous observations in mouse embryonic fibroblasts (29). Fragmented mitochondria are known to be heterogeneous with regard to their ΔΨm (8).

We therefore speculate that reduced hyperpolarization to oligomycin is due to an increased proportion of ATP-consuming mitochondria. In contrast, INS-1E cells expressing DN-Mfn1 retained oligomycin-induced hyperpolarization, which indicates that fragmentation of mitochondria per se does not alter control of the ΔΨm.

The lowered ATP levels in hFis1-overexpressing cells observed here are one of the consequences of mitochondrial dysfunction. Such cells actually compensated for their mitochondrial defect by accelerating glycolysis reflected by increased lactate production. This mechanism of compensation has also been observed in insulin-secreting βHC9 cells depleted of mtDNA (35). However, increased glycolysis cannot fully normalize cellular ATP levels in hFis1-overexpressing cells. In cells overexpressing DN-Mfn1, ATP levels were similar to control, and judging from the normal lactate response, mitochondrial activity was sufficient to maintain control ATP levels at both basal and stimulatory glucose concentrations. It is remarkable that despite similar mitochondrial fragmentation, the two transgenes had such strikingly different effects on mitochondrial energy metabolism.

Overexpression of wild type Mfn1 caused mitochondrial clumping, the result of excessive mitochondrial fusion in INS-1E cells as well as primary rat β-cells. To date, there is no information on the impact of mitochondrial hyperfusion by Mfn1 on mitochondrial energy metabolism. In this study, we show that Mfn1 overexpression reduced the ATP content, increased lactate production, and impaired glucose-stimulated insulin secretion. Consistent with our findings, several groups have reported that oxygen consumption and ATP generation are reduced in cells with highly fused mitochondria due to the down-regulation of fission proteins (14, 15).

It is interesting that INS-1E cells overexpressing hFis1 or WT-Mfn1 have a smaller total volume of mitochondria. Although we expected the reduced mitochondrial volume to be associated with decreased mtDNA copy number, direct quantitative PCR measurement of mtDNA did not substantiate this (data not shown). Reduced mitochondrial volume may, however, explain at least in part the observed reduced mitochondrial ATP production. In cells overexpressing DN-Mfn1, the mitochondrial volume was only little affected, and the fragmented organelles appeared to reach even peripheral areas of the cell. Taken together, there is a correlation between the mitochondrial volume and the ability of the cell to maintain cytosolic ATP levels on the one hand and to sense mitochondria-derived signals stimulating insulin secretion on the other.

In our study, hFis1 had a more marked impact on mitochondrial metabolism including reduction of MTT (reflecting oxi-
Mitochondrial Fission and Insulin Release

Acknowledgments—We are grateful to Danielle Nappey, Olivier Dupont, Dr. Françoise Assimacopoulos-Jeannet, Dr. Oliver Hartley, and Dr. Sergei Startchik.

REFERENCES

1. Bach, D., Pich, S., Soriano, F. X., Vega, N., Baumgartner, B., Oriola, J., Daugaard, J. R., Lloberas, J., Camps, M., Zierath, J. R., Rabasa-Lhoret, R., Wallberg-Henriksson, H., Laville, M., Palacin, M., Vidal, H., Rivera, F., Brand, M., and Zorzano, A. (2005) J. Biol. Chem. 278, 17190–17197

2. Chan, D. C. (2006) Annu. Rev. Cell Dev. Biol. 22, 79–99

3. James, D. I., Parone, P. A., Mattenerber, Y., and Martinou, J. C. (2003) J. Biol. Chem. 278, 36373–36379

4. Smirnova, E., Griparic, L., Shurland, D. L., and van der Bliek, A. M. (2001) Mol. Biol. Cell 12, 2245–2256

5. Yoon, Y., Krueger, E. W., Oswald, B. J., and McNiven, M. A. (2003) Mol. Cell. Biol. 23, 5409–5420

6. Stojanovski, D., Koutsopoulos, O. S., Okamoto, K., and Ryan, M. T. (2004) J. Cell Sci. 117, 1201–1210

7. Ishihara, N., Eura, Y., and Mihara, K. (2004) J. Cell Sci. 117, 6535–6546

8. Chen, H., Chomyn, A., and Chan, D. C. (2005) J. Biol. Chem. 280, 26185–26192

9. Santel, A., Frank, S., Gaume, B., Herrler, M., Youle, R. J., and Fuller, M. T. (2003) J. Cell Sci. 116, 2763–2774

10. Detmer, S. A., and Chan, D. C. (2007) Nat. Rev. Mol. Cell. Biol. 8, 870–879

11. Kim, I., Rodriguez-Enriquez, S., and Lemasters, J. J. (2007) Arch. Biochem. Biophys. 462, 245–253

12. Twig, G., Elorza, A., Molina, A. J., Mohamed, H., Wikstrom, J. D., Walzer, G., Stiles, L., Haigh, S. E., Katz, S., Las, G., Alroy, J., Wu, M., Py, B. F., Yuan, J., Deeney, J. T., Corkey, B. E., and Shirihi, O. S. (2008) EMBO J. 27, 433–446

13. Chen, H., Detmer, S. A., Ewald, A. J., Griffin, E. E., Fraser, S. E., and Chan, D. C. (2003) J. Cell Biol. 160, 189–200

14. Benard, G., Bellance, N., James, D., Parrone, P., Hernandez, F., Letellier, T., and Rossignol, R. (2007) J. Cell Sci. 120, 838–848

15. Lee, S., Jeong, S. Y., Lim, W. C., Kim, S., Park, Y. K., Sun, X., Youle, R. J., and Cho, H. (2007) J. Biol. Chem. 282, 22977–22983

16. Bindokas, V. P., Kuznetsov, A., Sreenan, S., Polonsky, K. S., Roe, M. W., and Philipson, L. H. (2003) J. Biol. Chem. 278, 9796–9801

17. Noske, A. B., Costin, A. J., Morgan, G. P., and Marsh, B. J. (2008) J. Struct. Biol. 161, 298–313

18. Schuit, F., De Vos, A., Farfari, S., Moens, K., Pipeleers, D., Brun, T., and Prentki, M. (1997) J. Biol. Chem. 272, 18572–18579

19. Wiedeker, A., and Wollheim, C. B. (2006) Endocrinology 147, 2613–2614

20. Kennedy, E. D., Maechler, P., and Wollheim, C. B. (1998) Diabetes 47, 374–380

21. Maassen, J. A., Janssen, G. M., and ’t Hart, L. M. (2005) Ann. Med. 37, 213–221

22. Murphy, R., Turnbull, D. M., Walker, M., and Hattersley, A. T. (2008) Diabet. Med. 25, 383–399

23. Denv, S., Vatamaniuk, M., Huang, X., Doliba, N., Lian, M. M., Frank, A., Velideodeglu, E., Desai, N. M., Koeberlein, B., Wolf, B., Barker, C. F., Naji, A., Matschinsky, F. M., and Markmann, J. F. (2004) Diabetes 53, 624–632

24. Anello, M., Lupi, R., Spinapinto, D., Piro, S., Masini, M., Boggi, U., Del Prato, S., Rabuazzo, A. M., Purrello, F., and Marchetti, P. (2005) Diabetologia 48, 282–289

25. Del Guerra, S., Lupi, R., Marselli, L., Masini, M., Bugliani, M., Sbrana, S.,
Torri, S., Pollera, M., Boggi, U., Mosca, F., Del Prato, S., and Marchetti, P. (2005) *Diabetes* **54**, 727–735
26. Maechler, P., Kennedy, E. D., Wang, H., and Wollheim, C. B. (1998) *J. Biol. Chem.* **273**, 20770–20778
27. Brun, T., Franklin, L., St-Onge, L., Biason-Lauber, A., Schoenle, E. J., Wollheim, C. B., and Gauthier, B. R. (2004) *J. Cell Biol.* **167**, 1123–1135
28. Ishihara, H., Maechler, P., Gjinovci, A., Herrera, P. L., and Wollheim, C. B. (2003) *Nat. Cell Biol.* **5**, 330–335
29. Alirol, E., James, D., Huber, D., Marchetto, A., Vergani, L., Martinou, J. C., and Scorrano, L. (2006) *Mol. Biol. Cell* **17**, 1123–1135
30. Zhang, Y., Soboloff, J., Zhu, Z., and Berger, S. A. (2006) *Mol. Pharmacol.* **70**, 1424–1434
31. Nagai, T., Yamada, S., Tominaga, T., Ichikawa, M., and Miyawaki, A. (2004) *Proc. Natl. Acad. Sci. U. S. A.* **101**, 10554–10559
32. Frieden, M., Arnaudeau, S., Castèelou, C., and Demaurex, N. (2005) *J. Biol. Chem.* **280**, 43198–43208
33. Lee, Y. J., Jeong, S. Y., Karbowski, M., Smith, C. L., and Youle, R. J. (2004) *Mol. Biol. Cell* **15**, 5001–5011
34. Janjic, D., and Wollheim, C. B. (1992) *Diabetologia* **35**, 482–485
35. Noda, M., Yamashita, S., Takahashi, N., Eto, K., Shen, L. M., Izumi, K., Daniel, S., Tsubamoto, Y., Nemoto, T., Iino, M., Kasai, H., Sharp, G. W., and Kadowaki, T. (2002) *J. Biol. Chem.* **277**, 41817–41826
36. Maechler, P., and Wollheim, C. B. (2001) *Nature* **414**, 807–812
37. Barsoum, M. J., Yuan, H., Gerencser, A. A., Liot, G., Kushnareva, Y., Graber, S., Kovacs, I., Lee, W. D., Waggner, J., Cui, J., White, A. D., Bossy, B., Martinou, J. C., Youle, R. J., Lipton, S. A., Ellisman, M. H., Perkins, G. A., and Bossy-Wetzel, E. (2006) *EMBO J.* **25**, 3900–3911
38. Zhou, Y. P., Pena, J. C., Roe, M. W., Mittal, A., Levisetti, M., Baldwin, A. C., Pugh, W., Ostrega, D., Ahmed, N., Biddokas, V. P., Philipson, L. H., Hanahan, D., Thompson, C. B., and Polonsky, K. S. (2000) *Am. J. Physiol.* **278**, E340–E351
39. Parone, P. A., James, D. I., Da Cruz, S., Mattenberger, Y., Donze, O., Barja, F., and Martinou, J. C. (2006) *Mol. Cell. Biol.* **26**, 7397–7408
40. Morigi, L. C., and Scorrano, L. (2008) *Biochim. Biophys. Acta* **1777**, 860–866
41. Gomes, L. C., and Scorrano, L. (2008) *Diabetes* **51**, 2944–2950
42. Celik, M., Forta, H., Parman, Y., Bissar-Tadmouri, N., Demirkirkan, K., and Battaloglu, E. (2001) *Diabet. Med.* **18**, 685–686
43. Koc, F., Sarica, Y., Yerdelen, D., Baris, I., Battaloglu, E., and Sert, M. (2006) *Int. J. Neurosci.* **116**, 103–114